Glaukos (GKOS) vs West Pharmaceutical Services (WST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Glaukos (GKOS) has outperformed West Pharmaceutical Services (WST) over the past year, gaining 104.8% versus a gain of 37.8%. Over five years, GKOS leads with a +284.2% price change compared with -9.5% for WST. West Pharmaceutical Services is the larger company by market cap ($25.79 billion vs $10.16 billion), about 2.5 times the size, while Glaukos is growing revenue faster (+32.3% vs +6.3%).
On valuation, West Pharmaceutical Services trades at a lower forward P/E (36.7x vs 328.9x for Glaukos). West Pharmaceutical Services pays a dividend yielding 0.24%, while Glaukos does not currently pay one. West Pharmaceutical Services converts more of its revenue into profit, with a net margin of 16.1% versus -37.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GKOS | WST |
|---|---|---|
| Share price | $172.18 | $366.48 |
| Market cap | $10.16B | $25.79B |
| 1-day change | +6.55% | -1.65% |
| YTD return | +52.49% | +33.20% |
| 1-year return | +104.76% | +37.79% |
| 5-year return | +284.16% | -9.47% |
| P/E ratio (TTM) | — | 46.92 |
| Forward P/E | 328.86 | 36.72 |
| EPS (TTM) | $-3.26 | $7.81 |
| Dividend yield | 0.00% | 0.24% |
| Annual dividend | $0.00 | $0.87 |
| Revenue (latest FY) | $507.44M | $3.07B |
| Revenue growth (YoY) | +32.33% | +6.25% |
| Net income (latest FY) | $-187.69M | $493.70M |
| Gross margin | 55.72% | 35.91% |
| Operating margin | -39.33% | 19.03% |
| Net margin | -36.99% | 16.06% |
| 52-week high | $191.62 | $386.00 |
| 52-week low | $73.16 | $223.83 |
| Distance from 52-week high | -10.15% | -5.06% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +15.40% | +12.15% |
| Average volume | 791.91K | 629.98K |
| Shares outstanding | 58.98M | 70.38M |
| Employees | 1,094 | 10,800 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- West Pharmaceutical Services is about 2.5 times larger than Glaukos by market value ($25.79B vs $10.16B).
- GKOS has outperformed WST by 67.0 percentage points over the past year.
- West Pharmaceutical Services is more profitable, keeping 16.1 cents of every revenue dollar as net income versus -37.0 cents for Glaukos.
- Glaukos grew revenue faster in its latest fiscal year (+32.33% vs +6.25%).
About Glaukos
GKOS stock →Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor.
Health Care · Medical/Dental Instruments · 1,094 employees
About West Pharmaceutical Services
WST stock →West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Health Care · Medical/Dental Instruments · 10,800 employees
GKOS vs WST FAQ
Which is bigger, Glaukos or West Pharmaceutical Services?
West Pharmaceutical Services (WST) is larger, with a market capitalization of $25.79B compared with $10.16B for Glaukos (GKOS).
Which stock has performed better over the past year, GKOS or WST?
GKOS returned +104.76% over the past 12 months, compared with +37.79% for WST (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Glaukos or West Pharmaceutical Services?
West Pharmaceutical Services pays a dividend yielding 0.24%, while Glaukos does not currently pay a regular dividend.
Are Glaukos and West Pharmaceutical Services in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.